Prostate Cancer ADT Has Fewer Cardiovascular Risks Than Expected
Investigators found that men receiving androgen deprivation therapy for prostate cancer had a 1% rate of major adverse cardiovascular events.
PROSTATE CANCER ADVISOR
Prostate Cancer
Features
-
-
Video May Aid in Precision Medicine for Prostate Cancer
In a study of men with prostate cancer or a family history of the disease, a higher proportion of men opted to view an educational video over personal genetic counseling prior to genetic testing. -
PSA Density Plus MRI May Improve Detection of Clinically Significant Prostate Cancer
Combining PSA density with prostate MRI findings improves the predictive performance of PI-RADS in men without a prior prostate cancer diagnosis. -
4Kscore May Help Predict Adverse Pathology at Radical Prostatectomy
In a study, a higher 4Kscore was significantly associated with a 16% greater risk of biochemical recurrence of prostate cancer following radical prostatectomy. -
SABR Found to Improve Outcomes in Recurrent Oligometastatic HSPC
In patients with recurrent oligometastatic hormone-sensitive prostate cancer, stereotactic ablative radiation therapy decreased the risk of disease progression compared with observation alone, a phase 2 study found. -
Genomic Alterations Linked to Outcomes in mCSPC
DNA sequencing in men with metastatic castration-sensitive prostate cancer revealed alterations in certain signaling pathways that predict worse overall survival and shorter progression time to castration-resistant disease. -
Prostate Cancer Immunotherapy Alone Is Not Enough
So far, prostate cancer immunotherapy has shown only modest benefits. To greatly improve outcomes, immunotherapy will need to be combined with other treatments, according to the authors of a recent review. -
Radiation Therapy After Prostate Surgery Worsens Sexual, Urinary Function
Allowing an approximately 24-month recovery period after prostate surgery before giving radiation therapy may be optimal for preserving erectile function provided oncologic control is not compromised, according to investigators.
Latest Prostate Cancer News
Severity of Sleep Apnea and Related Hypoxia Tied to Cancer
Sleep apnea and related hypoxia more severe in obstructive sleep apnea patients with cancer compared with those without cancer
Study: 177Lutetium-PSMA-617 After 223Radium for mCRPC Safe, Effective
Treatment with 177lutetium-PSMA-617 (177Lu-PSMA) is safe and effective in patients with metastatic castration-resistant prostate cancer (mCRPC) who have previously received 223radium (223Ra), according to study findings presented at the European Society for Medical Oncology’s 2022 Congress (ESMO 2022) in Paris, France. In a study of 133 patients who participated in the RALU trial, Kambiz Rahbar,…
Upstaging After PSMA PET for High-Risk Prostate Cancer Increasing
Study findings suggest that PSMA PET results may alter treatment decisions in high-risk prostate cancer.
Novel Hormonal Therapies for nmCRPC Underused, Data Show
Investigators characterized practice patterns in the first-line treatment of nonmetastatic castration-resistant prostate cancer using real-world data.
PRESTO: ADT Intensification Prolongs PSA PFS in Biochemically Recurrent Prostate Cancer
Phase 3 results appear to support intensification of ADT in patients with biochemically recurrent prostate cancer.
Survival Improving in Metastatic Castration-Sensitive Prostate Cancer Population
Increase in survival of men with mCSPC during 2015-2019 coincides with the use of docetaxel and novel hormonal therapies for this disease state.
Active Surveillance Best Suited for Older Men With Low-Risk Prostate Cancer
Investigators estimated disease trajectory and outcomes up to 30 years after the start of prostate cancer active surveillance.
Longer Course of ADT With Postop Radiotherapy Improves Metastasis-Free Survival in Prostate Cancer
Adding a longer course of androgen deprivation therapy to postoperative radiotherapy may prolong metastasis-free survival in patients with prostate cancer.
Genetic Risk Scores Show Promise in Predicting Risk of Prostate Cancer
Researchers sought to determine if genetic risk score could identify risk of prostate cancer in men with LUTS.
Metastasis-Directed Therapy for Prostate Cancer Found Beneficial Long-Term
MDT significantly prolonged progression-free survival, with the largest effect observed among patients with tumors harboring high-risk genetic mutations.
- Loading...
Loading...
Want to read more?
Please login or register first to view this content.
Next post in Prostate Cancer
Loading... 
Loading...